AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
MMJ Group today announced the expansion in annual production capacity in Toronto Stock Exchange-listed MediPharm Labs Inc.
Global cannabis investment company MMJ Group Holdings Limited (ASX:MMJ) holds 4.5% shareholding in MediPharm Labs that has announced an increase of 50% in its current annual production capacity. MediPharm Labs Corp stated that Health Canada had approved its wholly owned subsidiary, MediPharm Labs Inc. to increase its annual production from current processing capacity of up to 100,000 kg of dried cannabis over three extraction lines to 150,000 kg over five extraction lines.
The extension comes after MediPharm added two new extraction lines in its newly constructed extracted clean room along with the installation of other highly specialized and calibrated equipment. These new extraction lines have the potential to produce up to 6,500kg of cannabis resin on a yearly basis that is reportedly equivalent to ~9.7 million vape pens.
President and CEO of MediPharm Labs, Pat McCutcheon stated that the expansion outlines the companyâs ambition to become the global leader in the extraction of purified cannabis concentrates.
MediPharmâs focus is to build the differentiated extraction-only model while it moves towards the completion of Phase 2 expansion expected by the second quarter of 2019. This business model reportedly focuses on prioritizing the production of pharmaceutical-grade cannabis concentrate to achieve large-scale global distribution.
The companyâs Phase 2 expansion plan will see an increase in extraction capacity to up to 250,000kg of dried cannabis produced annually. Moreover, MediPharm stays positive for the receipt of regulatory approval to increase its production capacity.
Mr. McCutcheon added that the coming year is aimed at extraction in the cannabis industry and MediPharm is well positioned to service the demand for active ingredients required in the production of the most growing segment of the cannabis market like beverages, edibles, vapables, and topicals.
With this expansion, MediPharm claims to possess the largest extraction-only footprint in Canada with proprietary practices and ISO designed clean rooms and laboratories.
ASX listed Investor MMJ Group owns approximately 4.4 million shares in MediPharm Labs that makes it to 4.5% of total MediPharmâs shareholdings. It also holds 2.9 million warrants in MediPharm Labs that are exercisable at CAD$1.20 per share by October 2020.
It seems the growth in MediPharmâs production capacity has turned the investors' table to MMJ shares as MMJ Groupâs stock has gone up 5.128% to trade at $0.205 on 27 December 2018. Currently, 2:42 PM AEST, MMJ stock is trading at a price to earnings ratio of 1.490 with a market capitalization of $44.88 million. But since the past 12 months, it has shed 50.63% over the daily stock price movement.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
